Orphan designation: 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile Treatment of von Hippel-Lindau disease, 21/08/2020 Withdrawn

Orphan designation: 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile Treatment of von Hippel-Lindau disease, 21/08/2020 Withdrawn

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2324https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2324
Retrieved on: 
Tuesday, April 9, 2024
Information
Tags: 
Eurostat, Diagnosis, Civil service commission, Brain, Growth, Blood, Cell, Disease, Laser, Patient, Committee, Knowledge, Neoplasm, Regulation, EMA, IRIS, Eye, European, COMP, Pancreas, Spinal cord, Sponsor, European Commission, Von Hippel–Lindau disease, Gland, Safety, VHL, Marketing, DSM-IV codes, Medicine, Pharmaceutical industry
Geotags: 
EUROPEAN UNION, RARE, UNITED KINGDOM, EC, ICELAND, EU, NORWAY, NETHERLANDS, LIECHTENSTEIN
Summary
Key Points: 


Orphan designation: 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile Treatment of von Hippel-Lindau disease, 21/08/2020 Withdrawn

Copyright: 
2024 European Medicines Agency. All Rights Reserved.